Galera reports fourth quarter and full year 2021 financial results and recent corporate updates

Positive phase 3 roman trial of avasopasem for severe oral mucositis met primary and secondary endpoint; company intends to meet with fda in 2022 about nda submission
GRTX Ratings Summary
GRTX Quant Ranking